Rafaela Lopes Figueiredo de Andrade De Andrade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rafaela Lopes Figueiredo de Andrade De Andrade has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Paulo Guilherme de Oliveira Salles
INSTITUTO MÁRIO PENNA
3 shared publications - Carolina Pereira de Souza Melo
Laboratório de Pesquisa translacional em Oncologia, Núcleo de Ensino, Pesquisa e Inovação, Instituto Mário Penna
2 shared publications - Thalia Rodrigues de Souza Zózimo
Instituto de Ensino Pesquisa e Inovação- NEPI
2 shared publications - Aline Luiza Costa e Silva1 shared publication
- Ana Beatriz Ramos Do Nascimento
Instituto René Rachou - Fiocruz Minas, Belo Horizonte, Minas Gerais, Brazil / Instituto Mário Penna de Ensino, Pesquisa e Inovação - Laboratório de Pesquisa Translacional em Oncologia, Belo Horizonte, Minas Gerais, Brazil
1 shared publication - Ana Paula A.S. Ramos
Universidade Federal de São João del-Rei, Brazil
1 shared publication
Latest Publications
- Open Access
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 85-87
Identificação de variantes em genes da Via MAPK em uma coorte de pacientes com Câncer de Mama
Introdução O câncer de mama (CM) é o tipo de câncer mais prevalente entre mulheres em todo o mundo1. Globalmente, o CM foi responsável por cerca de 685 mil óbitos em 20202. No Brasil, estima-se cerca de 74 mil novos casos anuais de CM para o triênio 2023-2025, com uma taxa de mortalidade de 16,4%3. O CM representa uma alta carga de morbidade e mortalidade, com desafios como detecção tardia, barreiras socioeconômicas e baixa conscientização sobre a doença1. Neste contexto, estratégias baseadas em medicina personalizada (MP) poderão superar os desafios do manejo dessas pacientes. Objetivo Identificar variantes genômicas relacionadas à via de sinalização MAPK em uma coorte de pacientes com câncer de mama atendidas no Hospital Luxemburgo (HL). Métodos Alvos da via de sinalização MAPK1, presente no sequenciamento de 35 pacientes com CM obtido usando o QIAseq Multimodal Pan-Cancer Panel (Qiagen), foram selecionados no STRING DATABASE (anotação HSA-5684996 - intervalo de confiança ≥ 0.9). A chamada de variantes foi feita com o software QIAGEN CLC Genomics Workbench 23. Posteriormente, essas variantes foram classificadas no ClinVar para identificação de variantes associadas às vias canônicas e anotação de patogenicidade. Além disso, a associação da sobrevida das pacientes com CM e esse gene foi realizada no Kaplan-Meier Plotter (KMplot). Resultados Foram identificados 283 genes na via MAKP1. Scripts eliminaram duplicatas e definiram os genes comuns no Multimodal Panel, reduzindo a 55 genes. A chamada de variantes revelou 9.400 variantes nos 55 genes avaliados. Dos quais 11 genes foram predominantemente mutados. O IRS1 se destacou com o maior número de variantes identificadas (418), sendo: 1 provavelmente patogênica, 5 de significância incerta e 406 não reportadas. A análise no Kmplot mostrou que IRS1 mutado está associado a baixa sobrevida das pacientes com CM [HR 3,6 (1,14-11,33) p= 0,019]. Conclusão Esses resultados refletem uma elevada carga de alterações genéticas em genes-chave da via MAPK, frequentemente associados à progressão tumoral e resistência terapêutica. A classificação dessas variantes e sua relação com os desfechos clínicos das pacientes contribuirá para o entendimento das bases moleculares da CM e podem auxiliar na identificação de biomarcadores em prol da MP.
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 85-87
Open AccessIdentificação de variantes em genes da Via MAPK em uma coorte de pacientes com Câncer de Mama
Introdução O câncer de mama (CM) é o tipo de câncer mais prevalente entre mulheres em todo o mundo1. Globalmente, o CM foi responsável por cerca de 685 mil óbitos em 20202. No Brasil, estima-se cerca de 74 mil novos casos anuais de CM para o triênio 2023-2025, com uma taxa de mortalidade de 16,4%3. O CM representa uma alta carga de morbidade e mortalidade, com desafios como detecção tardia, barreiras socioeconômicas e baixa conscientização sobre a doença1. Neste contexto, estratégias baseadas em medicina personalizada (MP) poderão superar os desafios do manejo dessas pacientes. Objetivo Identificar variantes genômicas relacionadas à via de sinalização MAPK em uma coorte de pacientes com câncer de mama atendidas no Hospital Luxemburgo (HL). Métodos Alvos da via de sinalização MAPK1, presente no sequenciamento de 35 pacientes com CM obtido usando o QIAseq Multimodal Pan-Cancer Panel (Qiagen), foram selecionados no STRING DATABASE (anotação HSA-5684996 - intervalo de confiança ≥ 0.9). A chamada de variantes foi feita com o software QIAGEN CLC Genomics Workbench 23. Posteriormente, essas variantes foram classificadas no ClinVar para identificação de variantes associadas às vias canônicas e anotação de patogenicidade. Além disso, a associação da sobrevida das pacientes com CM e esse gene foi realizada no Kaplan-Meier Plotter (KMplot). Resultados Foram identificados 283 genes na via MAKP1. Scripts eliminaram duplicatas e definiram os genes comuns no Multimodal Panel, reduzindo a 55 genes. A chamada de variantes revelou 9.400 variantes nos 55 genes avaliados. Dos quais 11 genes foram predominantemente mutados. O IRS1 se destacou com o maior número de variantes identificadas (418), sendo: 1 provavelmente patogênica, 5 de significância incerta e 406 não reportadas. A análise no Kmplot mostrou que IRS1 mutado está associado a baixa sobrevida das pacientes com CM [HR 3,6 (1,14-11,33) p= 0,019]. Conclusão Esses resultados refletem uma elevada carga de alterações genéticas em genes-chave da via MAPK, frequentemente associados à progressão tumoral e resistência terapêutica. A classificação dessas variantes e sua relação com os desfechos clínicos das pacientes contribuirá para o entendimento das bases moleculares da CM e podem auxiliar na identificação de biomarcadores em prol da MP.
- Open Access
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 29-40
Evaluation of the OvarianTag biomarker panel's applicability in detecting Krukenberg tumors.
Krukenberg tumor is a metastatic ovarian adenocarcinoma, typically originating from the gastrointestinal tract, especially gastric cancer. It accounts for a significant proportion of ovarian tumors, being more common in Asian populations. These tumors usually affect younger women and have a poor prognosis. Diagnosis is challenging due to clinical similarities with other ovarian cancers, requiring a multimodal approach, including imaging tests, histopathological analysis, and biochemical markers. CA-125 may be useful in diagnosis but lacks specificity. Identifying molecular biomarkers specific to Krukenberg tumors could improve diagnosis and treatment. This study investigated the use of the OvarianTag® biomarker panel, developed to assess the prognosis of epithelial ovarian cancer (EOC), to differentiate between primary ovarian cancers and metastatic tumors from other sites, such as those from gastrointestinal origin. The research analyzed Krukenberg tumor samples and primary ovarian cancer samples, utilizing RNA extracted from tumor tissues and gene expression analysis by RT-qPCR. Despite genetic analysis, the OvarianTag® algorithm was unable to distinguish Krukenberg tumors from primary ovarian cancers accurately. The expression of genes TNFSRF10B, TNFSRF10C, and CASP8 showed no significant differences between the groups, and the algorithm failed to classify Krukenberg tumors correctly. These results suggest that OvarianTag® is not effective for this specific application, highlighting the need for new biomarkers to improve the diagnosis of metastatic ovarian tumors.
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 29-40
Open AccessEvaluation of the OvarianTag biomarker panel's applicability in detecting Krukenberg tumors.
Krukenberg tumor is a metastatic ovarian adenocarcinoma, typically originating from the gastrointestinal tract, especially gastric cancer. It accounts for a significant proportion of ovarian tumors, being more common in Asian populations. These tumors usually affect younger women and have a poor prognosis. Diagnosis is challenging due to clinical similarities with other ovarian cancers, requiring a multimodal approach, including imaging tests, histopathological analysis, and biochemical markers. CA-125 may be useful in diagnosis but lacks specificity. Identifying molecular biomarkers specific to Krukenberg tumors could improve diagnosis and treatment. This study investigated the use of the OvarianTag® biomarker panel, developed to assess the prognosis of epithelial ovarian cancer (EOC), to differentiate between primary ovarian cancers and metastatic tumors from other sites, such as those from gastrointestinal origin. The research analyzed Krukenberg tumor samples and primary ovarian cancer samples, utilizing RNA extracted from tumor tissues and gene expression analysis by RT-qPCR. Despite genetic analysis, the OvarianTag® algorithm was unable to distinguish Krukenberg tumors from primary ovarian cancers accurately. The expression of genes TNFSRF10B, TNFSRF10C, and CASP8 showed no significant differences between the groups, and the algorithm failed to classify Krukenberg tumors correctly. These results suggest that OvarianTag® is not effective for this specific application, highlighting the need for new biomarkers to improve the diagnosis of metastatic ovarian tumors.
- Open Access
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (1) , e20240824
Validation of cervical cancer genetic signature in minimally invasive samples
Cervical cancer remains the leading cause of cancer death in 36 countries, and high-risk human papillomavirus types are responsible for most cases. Identifying strategies to make treatment more targeted and effective has become a priority. This study aims to validate a set of differentially expressed genes previously identified in cervical cancer stem cells as predictive biomarkers for response to chemoradiotherapy using minimally invasive samples. Additionally, it aims to elucidate the relationship between high-risk human papillomavirus infection and cervical cancer patients’ response to treatment. Gene expression for three differentially expressed genes (COPZ1, ILF2, and SNX2) was evaluated from 20 cervical cancer patients’ cervical cytology brushes. Unmapped reads from the same transcriptome were used to evaluate the presence of human papillomavirus in tumor tissue through qualitative screening of 13 high-risk human papillomavirus types. Our study did not clarify the relationship between high-risk human papillomavirus infection and the treatment response. However, we found downregulation of COPZ1 in patients who responded to treatment compared to non-responders, and ILF2 in patients with more advanced tumor stages. This suggests that COPZ1 and ILF2 expressions are potential cervical cancer prognostic biomarkers that can be assessed using samples commonly used in clinical practice.
- 1 January 2025
- Published by FapUNIFESP (SciELO) in Anais da Academia Brasileira de Ciências
- Vol. 97 (1) , e20240824
Open AccessValidation of cervical cancer genetic signature in minimally invasive samples
Cervical cancer remains the leading cause of cancer death in 36 countries, and high-risk human papillomavirus types are responsible for most cases. Identifying strategies to make treatment more targeted and effective has become a priority. This study aims to validate a set of differentially expressed genes previously identified in cervical cancer stem cells as predictive biomarkers for response to chemoradiotherapy using minimally invasive samples. Additionally, it aims to elucidate the relationship between high-risk human papillomavirus infection and cervical cancer patients’ response to treatment. Gene expression for three differentially expressed genes (COPZ1, ILF2, and SNX2) was evaluated from 20 cervical cancer patients’ cervical cytology brushes. Unmapped reads from the same transcriptome were used to evaluate the presence of human papillomavirus in tumor tissue through qualitative screening of 13 high-risk human papillomavirus types. Our study did not clarify the relationship between high-risk human papillomavirus infection and the treatment response. However, we found downregulation of COPZ1 in patients who responded to treatment compared to non-responders, and ILF2 in patients with more advanced tumor stages. This suggests that COPZ1 and ILF2 expressions are potential cervical cancer prognostic biomarkers that can be assessed using samples commonly used in clinical practice.